Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies. A pilot study to determine ...
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the ESMO Congress 2025 ...
Title: A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring allosteric KRAS inhibitor, in patients with solid tumors with KRASG12D ...
Illumina Inc. (NASDAQ:ILMN) ranks among the top NASDAQ stocks with low P/E ratios. On September 23, Illumina Inc.
Verastem's high operational costs and recent rapid share price rise suggest that VSTM stock price is running hot. Read here ...
A recommendation to test for the mutation aligns with calls to identify biomarkers in cholangiocarcinoma to guide treatment. Testing for this mutation could guide treatment, wrote investigators from ...
Scientists at Memorial Sloan Kettering have discovered why certain drugs used to treat lung cancer are only partially effective. The findings point to combination therapies that might overcome this ...
A new-generation KRAS G12C inhibitor induced responses in more than half of patients with previously treated non-small cell lung cancer (NSCLC) harboring the mutation, a subgroup analysis of a phase I ...
Pharmaceutical Technology on MSN
Oceanpine Capital to acquire 80% equity stake in Beijing Jacoray
Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for 200m yuan ($28m).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback